# Sofinnova Investments

Sofinnova Investments is an Asset Manager based in Menlo Park, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Menlo Park, United States
- **Region:** North America
- **Address:** 3000 Sand Hill Road, Building 3-Suite 150, Menlo Park, CA 94025, United States
- **Founded:** 1976
- **Assets under management:** Undisclosed
- **Website:** sofinnova.com

## Regulatory record

- **CRD number:** 160297
- **SEC file number:** 801-110134
- **Registration status:** Registered
- **Reports private funds:** Yes
- **IAPD record:** https://adviserinfo.sec.gov/firm/summary/160297

## About

Sofinnova Investments is an SEC-registered investment adviser in Menlo Park, CA, registered since 2017. The firm manages $5.4 billion in regulatory assets. It has 41 employees and 20 investment advisers.

## Sectors

- Healthcare Services
- Digital Health

## Offices

- La Jolla, CA
- San Francisco, CA (historical)

## Questions

### How does Sofinnova Investments source its deal flow?

The firm sources therapeutic-company opportunities across the United States and Europe, leveraging a network built since its 1976 founding in Paris and its later independent U.S. presence. Board members and investment professionals originate deals through academic medical centers, biotech clusters, and relationships with serial life-science entrepreneurs. The dual-continent footprint gives it visibility into both FDA-oriented and EMA-oriented clinical-stage programs.

### Does Sofinnova Investments make public-market investments?

Yes, the firm operates a public-equity strategy focused on global therapeutics, complementing its core venture-capital activity. The public-equity effort invests in biopharmaceutical companies that are already listed, while the venture funds focus on private, clinical-stage drug developers.

### Which therapeutic areas does Sofinnova Investments avoid?

Sofinnova Investments concentrates on late-preclinical and clinical-stage therapeutics and has been primarily focused on drugs over the last decade. The firm does not list medical-device, diagnostics, or healthcare-services companies among its active portfolio, steering its capital toward areas such as oncology, neurology, ophthalmology, and rare disease.

### How is the firm's track record measured?

Sofinnova reports having funded 118 portfolio companies. Outcomes include initial public offerings — such as Seaport Therapeutics and BioAge Labs — and strategic acquisitions by large pharmaceutical companies including AstraZeneca, Roche, and Bristol Myers Squibb. The firm does not publicly disclose internal rates of return or distributed-to-paid-in multiples.

## Related profiles

- [Sofindev](https://altss.com/profile/sofindev)
- [Sofipaca](https://altss.com/profile/sofipaca)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/sofinnova-investments

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology